PSNL News and Press, Personalis Inc. From 02/23/22

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 p.m. Eastern Time. About Personalis Personalis, Inc. is a le...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a strategic collaboration with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support cli...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full-year 2021 financial results on Thursday, February 24, 2022. In conjunction with the release, the company will host a conference call and webcast th...

Personalis has seen a full boom and bust cycle again over the past year. Growth has slowed down and losses have increased, but fortunately the commercial side of the operations has seen a boost. Fundamentally, this remains a tough spot, but the cash position, modest sales multiple...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 2:00 p.m. Eastern Time. The webcast l...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2021. Personalis estimates revenue of approximately $20.7 million for the fourth ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 24 th Annual Needham Virtual Growth Conference on Tuesday, January 11, 2022. About Personalis Personalis, Inc. is a leader in advanced c...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Personal, a next-generation, tumor-informed liquid biopsy assay designed to detect and quantify molecular residual disease (MRD) and recurrence in patients previously diagnosed ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 33 rd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 1, 2021. Interested parties may access the pre-recorded and arch...

Personalis recognized in inaugural roundup for proven track record of management excellence Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has been named to Inc. ’s inaugural 2021 Best-Led Companies list ...